Anogenital warts related human papillomavirus. Anogenital (venereal) warts
Conditions
Interventions
Intervention 1: Intervention group: Participants will take one capsule containing 50,000 units of vitamin D orally every week for eight weeks. Intervention 2: Control group: Participants will take a p
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Having one or more anogenital wart(s) 20-70 years old
Exclusion criteria
Exclusion criteria: Treatment of warts by any method in the last month History of vitamin D allergy Users of vitamin D supplements Pregnancy Breastfeeding People suffering from other skin diseases Patients with immunosuppressive disorders, including diabetes, AIDS, and splenectomy Users of immunosuppressive medications including steroids, cytostatics and interferon, prednisone, orlistat, phenytoin, and thiazide diuretics may alter vitamin D levels. Users of drugs such as phenobarbital, carbamazepine, dexamethasone, nifedipine, spironolactone, clotrimazole, rifampin, which reduce vitamin D levels by producing hepatic cytochrome p450.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment response of the anogenital warts. Timepoint: The checklist related to the state of AGWs (size, location, and number) will be evaluated and completed before initiating the intervention, and the fourth and eighth weeks after the intervention. Method of measurement: The checklist related to the state of AGWs (size, location, and number); The response to treatment is considered according to the percentage of reduction in number of warts as follows: excellent (75-100% reduction of total wart count), very good (74-50% reduction), good (49-25% reduction), and poor (<25% reduction or no response). | — |
Secondary
| Measure | Time frame |
|---|---|
| The recurrence of anogenital warts during a 3-month follow-up period. Timepoint: After the completion of the treatment period, it will be recorded in the related checklist monthly for three months. Method of measurement: Checklist.;Human papillomavirus related quality of life (HPV-QoL) score. Timepoint: The HPV-QoL score will be measured once before the intervention, at the end of the intervention, and monthly during the 3-month follow-up period. Method of measurement: HPV-QoL questionnaire including 15 items.;Adverse events. Timepoint: Adverse events will be asked monthly on a specific day from the participants. Method of measurement: The adverse events will be asked of the participants by telephone and will be recorded in the relevant checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaba Tagizadeh milani
Tabriz University of Medical Sciences
Outcome results
None listed